Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Name:
37550302.pdf
Size:
348.8Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Coombes, R. C.Howell, Sacha J
Lord, S. R.
Kenny, L.
Mansi, J.
Mitri, Z.
Palmieri, C.
Chap, L. I.
Richards, P.
Gradishar, W.
Sardesai, S.
Melear, J.
O'Shaughnessy, J.
Ward, P.
Chalasani, P.
Arkenau, T.
Baird, R. D.
Jeselsohn, R.
Ali, S.
Clack, G.
Bahl, A.
McIntosh, S.
Krebs, Matthew G
Affiliation
Imperial College, South Kensington, London, UKIssue Date
2023
Metadata
Show full item recordAbstract
NoneCitation
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, et al. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature communications. 2023 Aug 7;14(1):4741. PubMed PMID: 37550302. Pubmed Central PMCID: PMC10406871. Epub 2023/08/08. eng.Journal
Nature CommunicationsDOI
10.1038/s41467-023-40561-xPubMed ID
37550302Additional Links
https://dx.doi.org/10.1038/s41467-023-40561-xType
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41467-023-40561-x
Scopus Count
Collections
Related articles
- Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
- Authors: Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG
- Issue date: 2023 Jul 24
- Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
- Authors: Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, Olden E, Penfold L, Ang S, Ormrod A, Leach DA, Lai CF, Ainscow EK, Bahl AK, Carling D, Fuchter MJ, Ali S, Bevan CL
- Issue date: 2024 Mar
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
- Authors: El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I
- Issue date: 2017 Jun 24
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
- Authors: Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M
- Issue date: 2019 Oct
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
- Authors: Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S
- Issue date: 2019 Jun